pISSN 1976-2283
eISSN 2005-1212

Cited by CrossRef (48)

  1. S. Sobrino-Cossío, O. Teramoto-Matsubara, G. Mateos-Pérez, J.M. Abdo-Francis, J. Tawil, C. Olguín-Ramírez, A. Orozco-Gamiz, E.S. Galvis-García. La búsqueda del Grial: una carrera por la supresión ácida. Revista de Gastroenterología de México 2019;84:344
    https://doi.org/10.1016/j.rgmx.2019.04.002
  2. Olasupo S. Adeniyi, Benjamin O. Emikpe, Samuel B. Olaleye. Accelerated gastric ulcer healing in thyroxine-treated rats: roles of gastric acid, mucus, and inflammatory response. Can. J. Physiol. Pharmacol. 2018;96:597
    https://doi.org/10.1139/cjpp-2017-0399
  3. Harilal Patel, Nirmal Desai, Prakash Patel, Nirav Modi, Krunal Soni, Jitendrakumar Rameshchandra Patel, Gaurav Navinbhai Mistry, Jitendrakumar D. Patel, Manish Chawla, Nuggehally R. Srinivas. Pharmacokinetic evaluation of differential drug release formulations of rabeprazole in dogs. Drug Development and Industrial Pharmacy 2019;45:1459
    https://doi.org/10.1080/03639045.2019.1628249
  4. Majid Eslami, Bahman Yousefi, Parviz Kokhaei, Ali Jazayeri Moghadas, Bizhan Sadighi Moghadam, Vahid Arabkari, Zohreh Niazi. Are probiotics useful for therapy of Helicobacter pylori diseases?. Comparative Immunology, Microbiology and Infectious Diseases 2019;64:99
    https://doi.org/10.1016/j.cimid.2019.02.010
  5. Óskar Ö. Hálfdánarson, Katja Fall, Margret H. Ogmundsdottir, Sigrún H. Lund, Eiríkur Steingrímsson, Helga M. Ogmundsdottir, Helga Zoega. Proton pump inhibitor use and risk of breast cancer, prostate cancer, and malignant melanoma: An Icelandic population‐based case‐control study. Pharmacoepidemiol Drug Saf 2019;28:471
    https://doi.org/10.1002/pds.4702
  6. Scott Klenzak, Igor Danelisen, Grace D Brannan, Melissa A Holland, Miranda AL van Tilburg. Management of gastroesophageal reflux disease: Patient and physician communication challenges and shared decision making. WJCC 2018;6:892
    https://doi.org/10.12998/wjcc.v6.i15.892
  7. Leon Fisher, Alexander Fisher. Acid-Suppressive Therapy and Risk of Infections: Pros and Cons. Clin Drug Investig 2017;37:587
    https://doi.org/10.1007/s40261-017-0519-y
  8. Ibrahim Masoodi. Prescription pattern of proton pump inhibitors among adults: A drug utilization study in the western region of Saudi Arabia.. IJMDC 2019:699
    https://doi.org/10.24911/IJMDC.51-1552663163
  9. Andy Liu, Bellal Jubran, Emeka K. Enwere, Megan Hansen, Nicole E. Burma, Yasmin Nasser. Reference Module in Biomedical Sciences. 2019.
    https://doi.org/10.1016/B978-0-12-801238-3.65617-9
  10. Russell Roark, Michael Sydor, Ahmed T. Chatila, Shifa Umar, Ramiro De La Guerra, Mohammad Bilal, Praveen Guturu. Management of gastroesophageal reflux disease. Disease-a-Month 2019
    https://doi.org/10.1016/j.disamonth.2019.02.002
  11. Andrea Corsonello, Fabrizia Lattanzio. Cardiovascular and non-cardiovascular concerns with proton pump inhibitors: Are they safe?. Trends in Cardiovascular Medicine 2019;29:353
    https://doi.org/10.1016/j.tcm.2018.10.008
  12. Yuta Yokoya, Ataru Igarashi, Akihito Uda, Hisato Deguchi, Toshihisa Takeuchi, Kazuhide Higuchi. Cost-utility analysis of a ‘vonoprazan-first’ strategy versus ‘esomeprazole- or rabeprazole-first’ strategy in GERD. J Gastroenterol 2019
    https://doi.org/10.1007/s00535-019-01609-2
  13. Lucija Kuna, Jelena Jakab, Robert Smolic, Nikola Raguz-Lucic, Aleksandar Vcev, Martina Smolic. Peptic Ulcer Disease: A Brief Review of Conventional Therapy and Herbal Treatment Options. JCM 2019;8:179
    https://doi.org/10.3390/jcm8020179
  14. Omar Kherad, Sophie Restellini, Myriam Martel, Alan Barkun. Proton pump inhibitors for upper gastrointestinal bleeding. Best Practice & Research Clinical Gastroenterology 2019:101609
    https://doi.org/10.1016/j.bpg.2019.04.002
  15. Yoshikazu Kinoshita, Motoyasu Kusano, Katsuhiko Iwakiri, Mitsuhiro Fujishiro, Naoto Tachikawa, Ken Haruma. Efficacy and Safety Profile of Z-215 (Azeloprazole Sodium), a Proton Pump Inhibitor, Compared with Rabeprazole Sodium in Patients with Reflux Esophagitis: A Phase II, Multicenter, Randomized, Double-Blind, Comparative Study. Current Therapeutic Research 2018;88:26
    https://doi.org/10.1016/j.curtheres.2018.03.004
  16. Michal Novotny, Blanka Klimova, Martin Valis. PPI Long Term Use: Risk of Neurological Adverse Events?. Front. Neurol. 2019;9
    https://doi.org/10.3389/fneur.2018.01142
  17. Yang Won Min, Danbee Kang, Ju-Young Shin, Minwoong Kang, Joo Kyung Park, Kwang Hyuck Lee, Jong Kyun Lee, Kyu Taek Lee, Poong-Lyul Rhee, Jae J. Kim, Eliseo Guallar, Juhee Cho, Hyuk Lee. Use of proton pump inhibitors and the risk of cholangitis: a nationwide cohort study. Aliment Pharmacol Ther 2019;50:760
    https://doi.org/10.1111/apt.15466
  18. Hyun Kang, Beom Jin Kim, Geunjoo Choi, Jae Gyu Kim. Vonoprazan versus proton pump inhibitors for the management of gastroesophageal reflux disease. Medicine 2018;97:e12574
    https://doi.org/10.1097/MD.0000000000012574
  19. Shahin Ayazi, Ping Zheng, Ali H. Zaidi, Kristy Chovanec, Nobel Chowdhury, Madison Salvitti, Yoshihiro Komatsu, Ashten N. Omstead, Toshitaka Hoppo, Blair A. Jobe. Magnetic Sphincter Augmentation and Postoperative Dysphagia: Characterization, Clinical Risk Factors, and Management. J Gastrointest Surg 2019
    https://doi.org/10.1007/s11605-019-04331-9
  20. S. Sobrino-Cossío, O. Teramoto-Matsubara, G. Mateos-Pérez, J.M. Abdo-Francis, J. Tawil, C. Olguín-Ramírez, A. Orozco-Gamiz, E.S. Galvis-García. In search of the grail: A race for acid suppression. Revista de Gastroenterología de México (English Edition) 2019;84:344
    https://doi.org/10.1016/j.rgmxen.2019.04.001
  21. Yu-Min Kung, Wen-Hung Hsu, Meng-Chieh Wu, Jiunn-Wei Wang, Chung-Jung Liu, Yu-Chung Su, Chao-Hung Kuo, Fu-Chen Kuo, Deng-Chyang Wu, Yao-Kuang Wang. Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease. Dig Dis Sci 2017;62:3298
    https://doi.org/10.1007/s10620-017-4830-5
  22. Shih-Wei Lai, Hsueh-Chou Lai, Cheng-Li Lin, Kuan-Fu Liao. Proton pump inhibitors and risk of gastric cancer in a case–control study. Gut 2019;68:765
    https://doi.org/10.1136/gutjnl-2018-316371
  23. Manuela Casula, Lorenza Scotti, Federica Galimberti, Francesco Mozzanica, Elena Tragni, Giovanni Corrao, Alberico L. Catapano. Use of proton pump inhibitors and risk of ischemic events in the general population. Atherosclerosis 2018;277:123
    https://doi.org/10.1016/j.atherosclerosis.2018.08.035
  24. Ekaterini Tiligada, Madeleine Ennis. Histamine pharmacology: from Sir Henry Dale to the 21st century. British Journal of Pharmacology 2018
    https://doi.org/10.1111/bph.14524
  25. Patrick J. Squires, Marco Pahor, Todd M. Manini, Joshua D. Brown. Effect of Gastric Acid Suppressants on Response to a Physical Activity Intervention and Major Mobility Disability in Older Adults: Results from the Lifestyle Interventions for Elders ( LIFE ) Study . Pharmacotherapy 2019;39:816
    https://doi.org/10.1002/phar.2299
  26. Satoshi Shinozaki, Hiroyuki Osawa, Yoshikazu Hayashi, Hirotsugu Sakamoto, Yoshimasa Miura, Alan Kawarai Lefor, Hironori Yamamoto. Vonoprazan treatment improves gastrointestinal symptoms in patients with gastroesophageal reflux disease. The Kaohsiung Journal of Medical Sciences 2017;33:616
    https://doi.org/10.1016/j.kjms.2017.07.004
  27. Sungpil Han, Hee Youn Choi, Yo Han Kim, Ji Yeon Nam, Bongtae Kim, Geun Seog Song, Hyeong-Seok Lim, Kyun-Seop Bae. Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 2019;50:751
    https://doi.org/10.1111/apt.15438
  28. Devulapally Srikrishna, Pramod Kumar Dubey. Synthesis of novel substituted 3-(4-((1H-benzo[d]imidazol-2-ylthio)methyl)-1-phenyl-1H-pyrazol-3-yl)-2H-chromen-2-ones: various approaches. Res Chem Intermed 2018;44:4455
    https://doi.org/10.1007/s11164-018-3397-x
  29. Amandeep Singh, Gail A. Cresci, Donald F. Kirby. Proton Pump Inhibitors: Risks and Rewards and Emerging Consequences to the Gut Microbiome. Nutrition in Clinical Practice 2018;33:614
    https://doi.org/10.1002/ncp.10181
  30. Wei-Te Hung, Ying-Hock Teng, Shun-Fa Yang, Han-Wei Yeh, Ying-Tung Yeh, Yu-Hsun Wang, Ming-Yung Chou, Ming-Chih Chou, Chi-Ho Chan, Chao-Bin Yeh. Association between Proton Pump Inhibitor Use and CNS Infection Risk: A Retrospective Cohort Study. JCM 2018;7:252
    https://doi.org/10.3390/jcm7090252
  31. Moon Kyung Joo, Jong-Jae Park, Hoon Jai Chun. Proton pump inhibitor: The dual role in gastric cancer. WJG 2019;25:2058
    https://doi.org/10.3748/wjg.v25.i17.2058
  32. Heba M. Eltahir, Maiiada H. Nazmy. Esomeprazole ameliorates CCl4 induced liver fibrosis in rats via modulating oxidative stress, inflammatory, fibrogenic and apoptotic markers. Biomedicine & Pharmacotherapy 2018;97:1356
    https://doi.org/10.1016/j.biopha.2017.11.028
  33. M. Naunton, G. M. Peterson, L. S. Deeks, H. Young, S. Kosari. We have had a gutful: The need for deprescribing proton pump inhibitors. J Clin Pharm Ther 2018;43:65
    https://doi.org/10.1111/jcpt.12613
  34. K. Renuka Prasad, Priyanka Chettri, N. A. Rajesh, A. Rathinaswamy, R. Padmanaban, T. M. Vijayakumar. Assessment of the risk of acute kidney injury associated with the use of pantoprazole and esomeprazole. Drugs Ther Perspect 2018;34:223
    https://doi.org/10.1007/s40267-018-0503-5
  35. Mariafrancesca Scalise, Lara Console, Michele Galluccio, Lorena Pochini, Annamaria Tonazzi, Nicola Giangregorio, Cesare Indiveri. Exploiting Cysteine Residues of SLC Membrane Transporters as Targets for Drugs. SLAS DISCOVERY: Advancing Life Sciences R&D 2019:247255521985660
    https://doi.org/10.1177/2472555219856601
  36. Nobuyuki Takahashi, Yukinori Take. Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility. J Pharmacol Exp Ther 2018;364:275
    https://doi.org/10.1124/jpet.117.244202
  37. Denis S. Fedorinov, Karin B. Mirzaev, Dmitriy V. Ivashchenko, Ilyas I. Temirbulatov, Dmitriy A. Sychev, Nadezda R. Maksimova, Jana V. Chertovskih, Nyurguiana V. Popova, Ksenia S. Tayurskaya, Zoya A. Rudykh. Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia). 2018;33:91
    https://doi.org/10.1515/dmpt-2018-0004
  38. Paulo Pimentel de Assumpção, Taíssa Maíra Thomaz Araújo, Paula Baraúna de Assumpção, Williams Fernandes Barra, André Salim Khayat, Carolina Baraúna Assumpção, Geraldo Ishak, Diana Noronha Nunes, Emmanuel Dias-Neto, Luiz Gonzaga Vaz Coelho. Suicide journey of H. pylori through gastric carcinogenesis: the role of non-H. pylori microbiome and potential consequences for clinical practice. Eur J Clin Microbiol Infect Dis 2019;38:1591
    https://doi.org/10.1007/s10096-019-03564-5
  39. Tigran Makunts, Isaac V. Cohen, Linda Awdishu, Ruben Abagyan. Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis. Sci Rep 2019;9
    https://doi.org/10.1038/s41598-019-39335-7
  40. Shun-Fa Yang, Chao-Bin Yeh. Reply to: Proton Pump Inhibitors and Risk of Pneumonia in Individuals with Dementia. J Am Geriatr Soc 2017;65:2547
    https://doi.org/10.1111/jgs.15084
  41. Carine Franco Morschel, Denise Mafra, José Carlos Carraro Eduardo. The relationship between proton pump inhibitors and renal disease. J. Bras. Nefrol. 2018;40:301
    https://doi.org/10.1590/2175-8239-jbn-2018-0021
  42. Ansar Mahmood, Afzal Shah, Suniya Shahzad, Saima Aftab, Latif-ur-Rahman, Jan Nisar, Aamir Hassan Shah. Monitoring of an Anti-Ulcer Drug Rabeprazole Using Au-Pt Bimetallic Alloy Nanoscale Electrochemical Sensor. J. Electrochem. Soc. 2017;164:H413
    https://doi.org/10.1149/2.0041707jes
  43. Pietro E. Lazzerini, Iacopo Bertolozzi, Francesco Finizola, Maurizio Acampa, Mariarita Natale, Francesca Vanni, Rosella Fulceri, Alessandra Gamberucci, Marco Rossi, Beatrice Giabbani, Michele Caselli, Ilaria Lamberti, Gabriele Cevenini, Franco Laghi-Pasini, Pier L. Capecchi. Proton Pump Inhibitors and Serum Magnesium Levels in Patients With Torsades de Pointes. Front. Pharmacol. 2018;9
    https://doi.org/10.3389/fphar.2018.00363
  44. Tatjana Bosnjak, Rigmor Solberg, Paya Diana Hemati, Abbas Jafari, Moustapha Kassem, Harald Thidemann Johansen. Lansoprazole inhibits the cysteine protease legumain by binding to the active site. Basic Clin Pharmacol Toxicol 2019
    https://doi.org/10.1111/bcpt.13230
  45. Manijeh Nematpour, Hossein Fasihi Dastjerdi, Sayyed Mohammad Ismaeil Mahboubi Rabbani, Sayyed Abbas Tabatabai. Copper‐Catalyzed Intramolecular N ‐Arylation of Dihalobenzene and Amine‐Trichloroacetonitrile Adduct under Ultrasound‐Irradiation . ChemistrySelect 2019;4:10299
    https://doi.org/10.1002/slct.201902411
  46. Domagoj Segregur, Talia Flanagan, James Mann, Andrea Moir, Eva M. Karlsson, Matthias Hoch, David Carlile, Sakina Sayah-Jeanne, Jennifer Dressman. Impact of Acid-Reducing Agents on Gastrointestinal Physiology and Design of Biorelevant Dissolution Tests to Reflect These Changes. Journal of Pharmaceutical Sciences 2019
    https://doi.org/10.1016/j.xphs.2019.06.021
  47. Robert T. Kavitt, Anna M. Lipowska, Adjoa Anyane-Yeboa, Ian M. Gralnek. Diagnosis and Treatment of Peptic Ulcer Disease. The American Journal of Medicine 2019;132:447
    https://doi.org/10.1016/j.amjmed.2018.12.009
  48. Geoffroy Desbuissons, Gilbert Deray, Lucile Mercadal. Inhibiteurs de la pompe à protons et rein. Néphrologie & Thérapeutique 2018;14:S115
    https://doi.org/10.1016/j.nephro.2017.06.005